NVO Novo Nordisk A/S

+1.37  (+3%)
Previous Close 50.29
Open 51.3
Price To Book 15.42
Market Cap 122,404,849,061
Shares 2,369,431,844
Volume 1,688,083
Short Ratio 2.27
Av. Daily Volume 1,587,854

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA filing announced March 20, 2019. Estimated PDUFA date September 20, 2019 assuming 6-month priority review.
Semaglutide - oral - PIONEER
Type 2 diabetes
Phase 3 trial to be initiated 4Q 2019.
Hemophilia A
Approval announced August 25, 2017.
Victoza (liraglutide)
Type 2 diabetes
Approved September 29, 2017.
Fiasp (fast-acting insulin aspart)
Type 1 and type 2 diabetes
Phase 3 trial initiated 2Q 2019.
Somapacitan (NN8640) - REAL 3
Growth Hormone Deficiency (GHD)
Phase 2 data released 2Q 2019.
Anti-IL 21 GLP-1 T1D (NNc)
Type 1 diabetes
Approval announced December 5, 2017.
Type 2 diabetes
Approval announced May 31, 2017.
Nonacog beta pegol
haemophilia B
FDA Approval announced February 19, 2019.
Hemophilia A
Phase 2 data due 4Q 2019.
Type 2 diabetes
Phase 2 trial initiated 1Q 2019.

Latest News

  1. Top Stock Reports for Cisco, Medtronic & Novo Nordisk
  2. UPDATE 2-Novo Nordisk contests Danish lawsuit claiming $1.75 bln
  3. Novo Nordisk sued in Denmark for alleged market manipulation - media
  4. Novo Nordisk Waits for Its Next Launch
  5. Calling life science innovators: don't miss your chance for a "Golden Ticket" to LabCentral
  6. How one Boston startup rode the diabetes investment wave to raise $126M
  7. Why Earnings Season Could Be Great for Novo Nordisk (NVO)
  8. Will These 3 Good Performers Beat the Market?
  9. Pharma Stock Roundup: AGN, NVO Earnings, EU Nod to SNY & ABBV Drugs for New Patients
  10. Novo Nordisk's new diabetes, obesity drugs lift sales outlook
  11. Novo Nordisk (NVO) Q2 Earnings & Revenues Beat Estimates
  12. NVS vs. NVO: Which Stock Should Value Investors Buy Now?
  13. If You Had Bought Novo Nordisk (CPH:NOVO B) Stock Five Years Ago, You Could Pocket A 32% Gain Today
  14. Diabetes drug maker Novo Nordisk buys pill factory in North Carolina
  15. Gilead-Galapagos Ink $5.1B Deal for Additional Compounds
  16. Pharma Stock Roundup: Pipeline & Regulatory Updates by MRK, GSK, SNY
  17. Sunnova Energy to offer 17.6 million shares in IPO, priced at $16 to $18 each
  18. Court Ruling Topples Trump Order, No Price Display in TV Ads
  19. Novo Nordisk Reports Encouraging Data From Hemophilia Studies
  20. Would Novo Nordisk A/S (CPH:NOVO B) Be Valuable To Income Investors?